Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice
Therapeutic Advances in Neurological Disorders
Published online on February 28, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:Siponimod, a selective sphingosine-1-phosphate receptor modulator was approved for patients with Secondary progressive Multiple Sclerosis (SPMS) with ongoing disease activity. However, its real-world positioning and management after ...
Background:Siponimod, a selective sphingosine-1-phosphate receptor modulator was approved for patients with Secondary progressive Multiple Sclerosis (SPMS) with ongoing disease activity. However, its real-world positioning and management after ...